Peptide YY sub(3-36) and Glucagon-Like Peptide-1 sub(7-36) Inhibit Food Intake Additively

Peptide YY (PYY) and glucagon like peptide (GLP)-1 are cosecreted from intestinal L cells, and plasma levels of both hormones rise after a meal. Peripheral administration of PYY sub(3-36) and GLP-1 sub(7-36) inhibit food intake when administered alone. However, their combined effects on appetite are unknown. We studied the effects of peripheral coadministration of PYY sub(3-36) with GLP-1 sub(7-36) in rodents and man. Whereas high-dose PYY sub(3-36) (100 nmol/kg) and high-dose GLP-1 sub(7-36) (100 nmol/kg) inhibited feeding individually, their combination led to significantly greater feeding inhibition. Additive inhibition of feeding was also observed in the genetic obese models, ob/ob and db/db mice. At low doses of PYY sub(3-36) (1 nmol/kg) and GLP-1 sub(7-36) (10 nmol/kg), which alone had no effect on food intake, coadministration led to significant reduction in food intake. To investigate potential mechanisms, c-fos immunoreactivity was quantified in the hypothalamus and brain stem. In the hypothalamic arcuate nucleus, no changes were observed after low-dose PYY sub(3-36) or GLP-1 sub(7-36) individually, but there were significantly more fos-positive neurons after coadministration. In contrast, there was no evidence of additive fos-stimulation in the brain stem. Finally, we coadministered PYY sub(3-36) and GLP-1 sub(7-36) in man. Ten lean fasted volunteers received 120-min infusions of saline, GLP-1 sub(7-36) (0.4 pmol/kg.min), PYY sub(3-36) (0.4 pmol/kg.min), and PYY sub(3-36) (0.4 pmol/kg.min) + GLP-1 sub(7-36) (0.4 pmol/kg.min) on four separate days. Energy intake from a buffet meal after combined PYY sub(3-36) + GLP-1 sub(7-36) treatment was reduced by 27% and was significantly lower than that after either treatment alone. Thus, PYY sub(3-36) and GLP-1 sub(7-36), cosecreted after a meal, may inhibit food intake additively.